Thomas Trolle

5PUBLICATIONS
12CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 21, 2025
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.

Christian Garde, Michail A Pavlidis, Pablo Garces

|May 27, 2023
DNA based neoepitope vaccination induces tumor control in syngeneic mouse models.

Nadia Viborg, Michail Angelos Pavlidis, Marina Barrio-Calvo

|Sep 01, 2022
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.

Georgina V Long, Pier Francesco Ferrucci, Adnan Khattak

|Jan 30, 2016
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove.

Curtis McMurtrey, Thomas Trolle, Tiffany Sansom

|Jan 20, 2016
The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference.

Thomas Trolle, Curtis P McMurtrey, John Sidney

Pageof 1

Frequent Collaborators

2 joint publications

Michail Angelos Pavlidis

2 joint publications

Birgitte Rønø

1 joint publications

John Sidney

1 joint publications

Thomas Kaever